Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$397.48 0.22 (0.06%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 103.36(B)
Last Volume: 682,467 Avg Vol: 1,619,368
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 67,740 152,280 258,193 599,211
Total Sell Value $28,555,052 $61,805,647 $99,413,137 $200,212,570
Total People Sold 8 12 15 18
Total Sell Transactions 28 41 68 132
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 3258
  Page 8 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2023-02-17 4 D $292.85 $1,098,188 D/D (3,750) 55,984     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2023-02-17 4 D $292.85 $1,098,188 D/D (3,750) 61,441     -
   Bozic Carmen EVP and CMO   •       –      –    2023-02-17 4 D $292.85 $1,098,188 D/D (3,750) 66,515     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2023-02-17 4 D $292.85 $1,317,239 D/D (4,498) 60,947     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2023-02-17 4 D $292.85 $1,098,188 D/D (3,750) 44,248     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2023-02-17 4 D $292.85 $1,024,389 D/D (3,498) 68,986     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2023-02-14 4 AS $300.29 $655,161 D/D (2,181) 59,734 16%     
   Arbuckle Stuart A EVP, COO   •       –      –    2023-02-14 4 AS $295.84 $1,910,962 D/D (6,398) 75,605 16%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2023-02-14 4 AS $295.89 $95,527 D/D (320) 65,445 16%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2023-02-14 4 AS $295.79 $1,911,108 D/D (6,398) 47,998 16%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2023-02-13 4 AS $296.44 $1,434,126 D/D (4,798) 54,396 16%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2023-02-13 4 D $298.26 $1,786,577 D/D (5,990) 59,194     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2023-02-13 4 AS $300.39 $33,944 D/D (113) 61,915 16%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2023-02-13 4 D $298.26 $1,294,448 D/D (4,340) 62,028     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2023-02-13 4 D $298.26 $1,388,997 D/D (4,657) 72,484     -
   Bozic Carmen EVP and CMO   •       –      –    2023-02-13 4 D $298.26 $1,488,914 D/D (4,992) 70,265     -
   Arbuckle Stuart A EVP, COO   •       –      –    2023-02-13 4 AS $296.44 $1,460,816 D/D (4,887) 82,003 16%     
   Arbuckle Stuart A EVP, COO   •       –      –    2023-02-13 4 D $298.26 $1,786,577 D/D (5,990) 86,890     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2023-02-13 4 D $298.26 $3,979,981 D/D (13,344) 62,079     -
   Kewalramani Reshma CEO & President   •       •      –    2023-02-13 4 D $298.26 $1,786,577 D/D (5,990) 148,714     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2023-02-13 4 AS $295.84 $82,223 D/D (275) 65,765 16%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2023-02-13 4 D $298.26 $893,289 D/D (2,995) 66,040     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2023-02-13 4 D $298.26 $1,488,914 D/D (4,992) 65,191     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2023-02-10 4 D $294.33 $1,018,676 D/D (3,461) 65,184     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2023-02-10 4 D $294.33 $265,486 D/D (902) 66,368     -
  3258 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us